Adore challenges conventional research paradigms by adopting a multidisciplinary approach that transcends traditional disease-specific frameworks. Rather than studying diseases solely within the confines of a single discipline—such as neurology or oncology—Adore fosters a broader, integrative perspective that encourages groundbreaking ideas beyond traditional scientific boundaries.

Currently, six out of seven focus groups are actively managing projects, each overseeing between one and three initiatives. Project funding ranges from €20,000 to €2,5 million, with additional investments in the pipeline.

Our funding strategy is designed to support both strong research infrastructure and cutting-edge innovation. Looking ahead, we will place greater emphasis on a “high-risk, low-cost” approach to accelerate implementation, foster breakthrough ideas, and maximize impact. At the same time, “low-risk, high-cost” proposals with strong innovation potential and high expected impact remain welcome.

The Dutch Research Council (NWO) has awarded Adore €9 million as part of its €25 million KIC-LTP funding initiative, which aims to address pressing societal challenges such as the rising rates of cancer and neurodegenerative diseases in the Netherlands. With this support, Adore is launching a 10-year, €30 million interdisciplinary research program. The program brings together public and private partners, including Vrije Universiteit Amsterdam, Leiden University Medical Center, UMC Utrecht, TU Delft and OMAPiX. Leading experts from oncology, neurology, data science, and ethics are united in this unique collaboration, supported by a dedicated research facility and significant private funding. Through this consortium, Adore stimulates the development of new therapies, diagnostic tools, and precision medicine.

Below, you will find an overview of previously funded projects and their details. Proposals that are currently under review are also higlighted.